FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
31/10/2025
Voltar para busca
Dado oficial do USPTO
RIBOCURE PHARMACEUTICALS AB
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
26
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42
Data de depósito
29/12/2023
Data de registro
01/04/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
01/04/2025
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
64
Localização do titular
SE
Examinador
KEAN, AMY C
Unidade examinadora
N30
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of the stylized wording "Ribocure" in black with the tittle over the letter "i" in orange and the letter "o" being formed by two curved vertical curves with the left curve in orange and the right curve in black, all over the stylized wording "Pharmaceuticals AB" in black, with all of the foregoing to the right of a stylized caduceus formed by a staff with a ball on top with one curving bar in black and a smaller waving ribbon over the bar in orange.
Titulares e representantes
Titulares
Ribocure Pharmaceuticals AB
Representantes
Zhi Dong HSML, P.C.
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
medicines for humans for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; crude drugs being pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; chemico-pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; biological preparations for medical purposes for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; chemical preparations for pharmaceutical purposes for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; chemical preparations for medical purposes for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; drugs for medical purposespharmaceutical preparations for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; diagnostic preparations for medical purposes; potassium salts for medical purposes; sodium salts for medical purposes; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations; biological preparations for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; tumor suppressing agents; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the central nervous system; medicinal preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating metabolic disorders; anticoagulants; cardiovascular pharmaceutical preparations; pharmaceutical preparations for ocular or intraocular surgery; depuratives for the body; veterinary preparations for the treatment and diagnosis of gastrointestinal diseasescardiovascular diseasesmetabolic diseasesliver diseases; pesticides; medical dressings; composite materials for dental purposes; diapers for pets
Classe 42
technological research in the field of pharmaceutical manufacturing processes and pharmaceutical studies; pharmaceutical drug development services; pharmaceutical product evaluation; pharmaceutical research services; pharmaceutical research and development services; scientific research; chemical research and analysis; development and test of chemical production methods; biochemical research and analysis; development of pharmaceutical preparations and medicines; scientific research in the nature of conducting clinical trials for others; medical research; testing of pharmaceuticals; industrial design
Publicações
Histórico de despachos e eventos da marca no USPTO.
26 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
14/10/2025
FIMP
FINAL DISPOSITION PROCESSED
14/10/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
01/08/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
14/07/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
14/07/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/07/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/04/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
01/04/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/02/2025
PUBO
PUBLISHED FOR OPPOSITION
11/02/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/02/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/01/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/01/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/01/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/01/2025
RFNT
REFUSAL PROCESSED BY IB
08/09/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
16/08/2024
RFRR
REFUSAL PROCESSED BY MPU
16/08/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/08/2024
CNRT
NON-FINAL ACTION WRITTEN
07/08/2024
DOCK
ASSIGNED TO EXAMINER
28/07/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
13/04/2024
MAFR
APPLICATION FILING RECEIPT MAILED
27/02/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
21/02/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
15/02/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace RIBOCURE PHARMACEUTICALS AB ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.